Skip to main content
Erschienen in: Indian Journal of Hematology and Blood Transfusion 1/2016

01.03.2016 | Original Article

Changes of Apolipoprotein M Gene Expression During the Cell Differentiation and Apoptosis Induced by Simvastatin in Combination with All-Trans Retinoic Acid in Human Promyelocytic Leukemia Cell Line NB4

verfasst von: Weiying Gu, Lili Xiang, Tingxiu Jiang, Guanghua Luo, Jiang Wei, Jiannong Cen, Zixing Chen, Guoqiang Qiu, Mei Zeng, Xiaoying Zhang

Erschienen in: Indian Journal of Hematology and Blood Transfusion | Ausgabe 1/2016

Einloggen, um Zugang zu erhalten

Abstract

We examined the effect of simvastatin (SV) alone and in combination with all-trans retinoic acid (ATRA) on proliferation, differentiation, apoptosis and apolipoprotein M (apoM) expression in the human promyelocytic leukemia cell line NB4. The NB4 cells were incubated with 10 μM Simvastatin (10SV) and 0.5 μM ATRA alone or in combination, taking NB4 cells without any treatment as normal controls. The cells of different groups were collected at 24, 48 and 72 h post-incubation for further detection. Their morphological changes were observed after Wright stain. MTT method was used to assay the growth inhibition rate and flow cytometry to detect CD11b expression level and the early stage apoptosis ratio. Real-time quantitative reverse transcriptase-polymerase chain reaction was used to detect the apoM gene expression levels. As expected 0.5 μM ATRA did not affect proliferation or apoptosis, strongly induced differentiation and decreased apoM expression. 10SV inhibited proliferation, increased apoptosis, induced differentiation and increased apoM expression in a time-dependent manner. The addition of ATRA to SV did not increase the effect of SV on proliferation and apoptosis, but increased the effect of SV on differentiation. And completely abrogated the effect of SV on apoM expression. Together these results show that SV has anti-leukemic properties by itself and that combined therapy may have a place in the current anti-leukemic arsenal.
Literatur
1.
Zurück zum Zitat Chan KK, Oza AM, Siu LL (2003) The statins as anticancer agents. Clin Cancer Res 9:10–19PubMed Chan KK, Oza AM, Siu LL (2003) The statins as anticancer agents. Clin Cancer Res 9:10–19PubMed
2.
Zurück zum Zitat Brower V (2003) Of cancer and cholesterol: studies elucidate anticancer mechanisms of statins. J Natl Cancer Inst 95:844–846CrossRefPubMed Brower V (2003) Of cancer and cholesterol: studies elucidate anticancer mechanisms of statins. J Natl Cancer Inst 95:844–846CrossRefPubMed
3.
Zurück zum Zitat Demierre MF, Higgins PD, Gruber SB, Hawk E, Lippman SM (2005) Statins and cancer prevention. Nat Rev Cancer 5:930–942CrossRefPubMed Demierre MF, Higgins PD, Gruber SB, Hawk E, Lippman SM (2005) Statins and cancer prevention. Nat Rev Cancer 5:930–942CrossRefPubMed
4.
5.
Zurück zum Zitat Hindler K, Cleeland CS, Rivera E, Collard CD (2006) The role of statins in cancer therapy. Oncologist 11:306–315CrossRefPubMed Hindler K, Cleeland CS, Rivera E, Collard CD (2006) The role of statins in cancer therapy. Oncologist 11:306–315CrossRefPubMed
6.
Zurück zum Zitat Tomiyama N, Matzno S, Kitada C, Nishiguchi E, Okamura N, Matsuyama K (2008) The possibility of simvastatin as a chemotherapeutic agent for all-trans retinoic acid-resistant promyelocytic leukemia. Biol Pharm Bull 31:369–374CrossRefPubMed Tomiyama N, Matzno S, Kitada C, Nishiguchi E, Okamura N, Matsuyama K (2008) The possibility of simvastatin as a chemotherapeutic agent for all-trans retinoic acid-resistant promyelocytic leukemia. Biol Pharm Bull 31:369–374CrossRefPubMed
7.
Zurück zum Zitat Sassano A, Katsoulidis E, Antico G, Katsoulidis E, Antico G, Altman JK, Redig AJ, Minucci S, Tallman MS, Platanias LC (2007) Suppressive effects of statins on acute promyelocytic leukemia cells. Cancer Res 67:4524–4532CrossRefPubMed Sassano A, Katsoulidis E, Antico G, Katsoulidis E, Antico G, Altman JK, Redig AJ, Minucci S, Tallman MS, Platanias LC (2007) Suppressive effects of statins on acute promyelocytic leukemia cells. Cancer Res 67:4524–4532CrossRefPubMed
8.
9.
Zurück zum Zitat Zhang XY, Dong X, Zheng L, Luo GH, Liu YH, Ekstrom U, Nilsson-Ehle P, Ye Q, Xu N (2003) Specific tissue expression and cellular localization of human apolipoprotein M as determined by in situ hybridization. Acta Histochem 105:67–72CrossRefPubMed Zhang XY, Dong X, Zheng L, Luo GH, Liu YH, Ekstrom U, Nilsson-Ehle P, Ye Q, Xu N (2003) Specific tissue expression and cellular localization of human apolipoprotein M as determined by in situ hybridization. Acta Histochem 105:67–72CrossRefPubMed
10.
Zurück zum Zitat Luo G, Zhang X, Mu Q, Chen L, Zheng L, Wei J, Berggren-Soderlund M, Nilsson-Ehle P, Xu N (2010) Expression and localization of apolipoprotein M in human colorectal tissues. Lipids Health Dis 9:102PubMedCentralCrossRefPubMed Luo G, Zhang X, Mu Q, Chen L, Zheng L, Wei J, Berggren-Soderlund M, Nilsson-Ehle P, Xu N (2010) Expression and localization of apolipoprotein M in human colorectal tissues. Lipids Health Dis 9:102PubMedCentralCrossRefPubMed
11.
Zurück zum Zitat Hatake K, Uwai M, Ohtsuki T, Tomizuka H, Izumi T, Yoshida M, Miura Y (1997) Rare but important adverse effects of all-trans retinoic acid in acute promyelocytic leukemia and their management. Int J Hematol 66:13–19CrossRefPubMed Hatake K, Uwai M, Ohtsuki T, Tomizuka H, Izumi T, Yoshida M, Miura Y (1997) Rare but important adverse effects of all-trans retinoic acid in acute promyelocytic leukemia and their management. Int J Hematol 66:13–19CrossRefPubMed
12.
Zurück zum Zitat Gu W, Hu S, He B, Qiu G, Ma J, Chen Z (2009) Metabolites of acute promyelocytic leukemia cells participate in contributing to hypertriglyceridemia induced by all-trans retinoic acid. Leuk Res 33:592–594CrossRefPubMed Gu W, Hu S, He B, Qiu G, Ma J, Chen Z (2009) Metabolites of acute promyelocytic leukemia cells participate in contributing to hypertriglyceridemia induced by all-trans retinoic acid. Leuk Res 33:592–594CrossRefPubMed
13.
Zurück zum Zitat Wang ZY, Chen Z (2008) Acute promyelocytic leukemia: from highly fatal to highly curable. Blood 111:2505–2515CrossRefPubMed Wang ZY, Chen Z (2008) Acute promyelocytic leukemia: from highly fatal to highly curable. Blood 111:2505–2515CrossRefPubMed
14.
Zurück zum Zitat van der Weide K, de Jonge-Peeters SD, Kuipers F, Vries EG, Vellenga E (2009) Combining simvastatin with the farnesyltransferase inhibitor tipifarnib results in an enhanced cytotoxic effect in a subset of primary CD34 + acute myeloid leukemia samples. Clin Cancer Res 15:3076–3083CrossRefPubMed van der Weide K, de Jonge-Peeters SD, Kuipers F, Vries EG, Vellenga E (2009) Combining simvastatin with the farnesyltransferase inhibitor tipifarnib results in an enhanced cytotoxic effect in a subset of primary CD34 + acute myeloid leukemia samples. Clin Cancer Res 15:3076–3083CrossRefPubMed
15.
Zurück zum Zitat Ho YK, Smith RG, Brown MS, Goldstein JL (1978) Low-density lipoprotein (LDL) receptor activity in human acute myelogenous leukemia cells. Blood 52:1099–1114PubMed Ho YK, Smith RG, Brown MS, Goldstein JL (1978) Low-density lipoprotein (LDL) receptor activity in human acute myelogenous leukemia cells. Blood 52:1099–1114PubMed
16.
Zurück zum Zitat Firestone RA (1994) Low-density lipoprotein as a vehicle for targeting antitumor compounds to cancer cells. Bioconjug Chem 5:105–113CrossRefPubMed Firestone RA (1994) Low-density lipoprotein as a vehicle for targeting antitumor compounds to cancer cells. Bioconjug Chem 5:105–113CrossRefPubMed
17.
Zurück zum Zitat Vitols S, Norgren S, Juliusson G, Tatidis L, Luthman H (1994) Multilevel regulation of low-density lipoprotein receptor and 3-hydroxy-3-methylglutaryl coenzyme A reductase gene expression in normal and leukemic cells. Blood 84:2689–2698PubMed Vitols S, Norgren S, Juliusson G, Tatidis L, Luthman H (1994) Multilevel regulation of low-density lipoprotein receptor and 3-hydroxy-3-methylglutaryl coenzyme A reductase gene expression in normal and leukemic cells. Blood 84:2689–2698PubMed
18.
Zurück zum Zitat Li HY, Appelbaum FR, Willman CL, Zager RA, Banker DE (2003) Cholesterol-modulating agents kill acute myeloid leukemia cells and sensitize them to therapeutics by blocking adaptive cholesterol responses. Blood 101:3628–3634CrossRefPubMed Li HY, Appelbaum FR, Willman CL, Zager RA, Banker DE (2003) Cholesterol-modulating agents kill acute myeloid leukemia cells and sensitize them to therapeutics by blocking adaptive cholesterol responses. Blood 101:3628–3634CrossRefPubMed
19.
Zurück zum Zitat Banker DE, Mayer SJ, Li HY, Willman CL, Appelbaum FR, Zager RA (2004) Cholesterol synthesis and import contribute to protective cholesterol increments in acute myeloid leukemia cells. Blood 104:1816–1824CrossRefPubMed Banker DE, Mayer SJ, Li HY, Willman CL, Appelbaum FR, Zager RA (2004) Cholesterol synthesis and import contribute to protective cholesterol increments in acute myeloid leukemia cells. Blood 104:1816–1824CrossRefPubMed
20.
Zurück zum Zitat Christoffersen C, Obinata H, Kumaraswamy SB, Galvani S, Ahnstrom J, Sevvana M, Egerer-Sieber C, Muller YA, Hla T, Nielsen LB, Dahlback B (2011) Endothelium-protective sphingosine-1-phosphate provided by HDL-associated apolipoprotein M. Proc Natl Acad Sci USA 108:9613–9618PubMedCentralCrossRefPubMed Christoffersen C, Obinata H, Kumaraswamy SB, Galvani S, Ahnstrom J, Sevvana M, Egerer-Sieber C, Muller YA, Hla T, Nielsen LB, Dahlback B (2011) Endothelium-protective sphingosine-1-phosphate provided by HDL-associated apolipoprotein M. Proc Natl Acad Sci USA 108:9613–9618PubMedCentralCrossRefPubMed
Metadaten
Titel
Changes of Apolipoprotein M Gene Expression During the Cell Differentiation and Apoptosis Induced by Simvastatin in Combination with All-Trans Retinoic Acid in Human Promyelocytic Leukemia Cell Line NB4
verfasst von
Weiying Gu
Lili Xiang
Tingxiu Jiang
Guanghua Luo
Jiang Wei
Jiannong Cen
Zixing Chen
Guoqiang Qiu
Mei Zeng
Xiaoying Zhang
Publikationsdatum
01.03.2016
Verlag
Springer India
Erschienen in
Indian Journal of Hematology and Blood Transfusion / Ausgabe 1/2016
Print ISSN: 0971-4502
Elektronische ISSN: 0974-0449
DOI
https://doi.org/10.1007/s12288-015-0515-4

Weitere Artikel der Ausgabe 1/2016

Indian Journal of Hematology and Blood Transfusion 1/2016 Zur Ausgabe

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

25.04.2024 NSCLC Nachrichten

Das Risiko für Rezidiv oder Tod von Patienten und Patientinnen mit reseziertem ALK-positivem NSCLC ist unter einer adjuvanten Therapie mit dem Tyrosinkinase-Inhibitor Alectinib signifikant geringer als unter platinbasierter Chemotherapie.

Bei Senioren mit Prostatakarzinom auf Anämie achten!

24.04.2024 DGIM 2024 Nachrichten

Patienten, die zur Behandlung ihres Prostatakarzinoms eine Androgendeprivationstherapie erhalten, entwickeln nicht selten eine Anämie. Wer ältere Patienten internistisch mitbetreut, sollte auf diese Nebenwirkung achten.

ICI-Therapie in der Schwangerschaft wird gut toleriert

Müssen sich Schwangere einer Krebstherapie unterziehen, rufen Immuncheckpointinhibitoren offenbar nicht mehr unerwünschte Wirkungen hervor als andere Mittel gegen Krebs.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.